San Francisco, California
London, United Kingdom
This interactive breakfast will focus on the changing Healthcare landscape between customer, payers, and providers and the changing business model within the medical technology sector. The session will also focus on Deloitte’s capabilities within ConvergeHEALTH – a suite of analytical tools for achieving personalized healthcare and more extensive research solutions. Participants will also have the opportunity to hear from a panel of experts within the lifesciences and med tech field, and gain insight on leading practices and lessons learned.
An overview of the workshop topics includes:
- Changing landscape
- Aims of ConvergeHEALTH by Deloitte
– Clinical and operational excellence
– Value based care
– Research excellence: clinical and translational capabilities
Med Tech Industry Overview:
- Current state overview
- Changing business model
– Future state
– New opportunities
Med Tech: Oriented to three Rules
- Better before cheaper
– Stop competing on price
– Value based competition
- Revenue before cost
– Higher volume and price vs lower cost
– Generation of sustainable revenue
- Remain aligned with the first two rules
Med Tech: four Pillars:
- Broader view of innovation
- New commercial models
- Effective value articulation
- Advanced pricing
Adaptations to the Rules and Pillars :
- Traditional med tech business models are becoming obsolete
- Forward looking industry transformation
Glenn H. Snyder - Principal, Lifesciences Strategy and Operations, Deloitte Consulting LLP
Glenn Snyder is a Principal with Deloitte Consulting, LLP. He currently leads Deloitte Consulting's Medical Technology practice as well as the Industry Eminence Program for Life Sciences and Health Care Consulting. He has been serving the life sciences and healthcare industry as a consultant since 1989 and has been with Deloitte since 1995. Glenn's expertise is within strategy for the life sciences sector, with deep experience in medical technology, biotech and specialty pharmaceuticals. He has helped clients price products, gain better net reimbursement, articulate product economic value, launch new products, improve market access and rationalize distribution networks. He has also helped clients expand in new/emerging markets and has conducted insightful research and presented on this topic. Glenn has tackled issues across the healthcare value chain over the course of his career, including the payor and provider sectors. Recently, Glenn has helped several life sciences companies navigate changes in the healthcare ecosystem (including those specific to health reform) by modifying their commercial model, and developing tangible growth plans that incorporate maturity aspirations, external pressures and internal pipeline expectations. An eminent speaker and thought leader, Glenn has presented at notable conferences, including CalBIO2012, Bio/Pharma Trade Channel Strategies, BIO International Convention, BayBio, and Analytical and Lifesciences Systems Association. Glenn has also published several articles and whitepapers through Deloitte, Deloitte Review, Pharma Processing, and Future Pharma. Glenn holds a Master of Business Administration in Finance and Strategic Management from the Wharton School of the University of Pennsylvania, a Master of Science in Engineering from the University of Southern California, and a Bachelor of Science in Engineering from Cal Poly, San Luis Obispo. Glenn is an avid mountain biker, and is involved in governing and advisory boards of two educational institutions.
David Hardison – Western Region Leader, ConvergeHEALTH Deloitte
David is a seasoned executive and consultant with over 30 years of leadership, P/L experience and insight at the intersection of biopharmaceutical R&D, healthcare delivery, performance improvement, and information technology. Currently, David is a western region leader of ConvergeHEALTH, a new business unit in Deloitte focused on helping clients succeed in the new world of value-based, personalized medicine. David also has been CIO of a health system and advised healthcare executive teams and boards. He provides industry leadership as a member of the board of directors of CDISC (Clinical Data Interchange Standards Consortium) where he was recently elected as the next chairman of the board. CDISC’s mission is to develop and support global, platform-independent data standards that enable information system interoperability to improve medical research and related areas of healthcare. CDISC’s over 350 members include most of the world’s biopharmaceutical and medical technology companies, CROs and regulatory authorities.
Amit Agarwal – Principal, Deloitte Consulting
Amit has more than 20 years of management consulting experience and has led multiple projects in both strategy and operational improvement for biotech, medical device, diagnostic and life science tools clients. His specialty is helping clients adopt to disruptive change fueled by innovative new technologies, changing business models, international competition and regulatory shifts. He has helped senior management teams of life science clients in the U.S., Europe and Asia grapple with critical issues. Amit has published extensively on the life sciences industry, regularly presents at industry conferences and been quoted in both the industry and popular press. In addition to his consulting experience, Amit has also helped innovative life science companies raise capital, identify merger and acquisition targets and negotiate strategic partnerships and alliances as an investment banker. He helped his clients generate nearly $1billion of market value through the deals he helped broker. Prior to business school, Amit conducted research in neurobiology at the California Institute of Technology and was an American diplomat posted in China and the Middle East. Amit holds an MBA in finance and technological innovation from the MIT Sloan School of Management and a bachelor’s degree in history and pre-med from Occidental College.
Breakfast will be served.
When & Where